menu

The Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease

5 chapters
Play All
1.00 credits
60 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of retinal vascular diseases. Dual inhibition therapy that acts on 2 pathways—VEGF-A and angiopoietin-2 (Ang-2)—is now available. Are 2 pathways better than 1? Find out in this engaging roundtable-style eye care forum, which will demonstrate direct comparisons of dual anti-Ang-2/VEGF-A therapy and anti-VEGF monotherapy, enhanced by real-life case studies and anecdotes from the expert faculty members’ own practices. 

  • Target Audience

    This activity has been designed to address the educational needs of retina specialists and comprehensive ophthalmologists. It may also benefit other clinicians involved in the care of patients with retinal vascular diseases.

  • Educational Provider

    This activity is provided by Paradigm Medical Communications, LLC.   

     

  • Commercial Support

    This activity is supported by an educational grant from Genentech, a member of the Roche Group.

  • Learning Objectives

    Upon completion of this activity, participants should be able to: 

    • Describe the significance of Ang-2 inhibition in combination with VEGF-A inhibition in the development and progression of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) 

    • Distinguish dual inhibition therapy from anti-VEGF therapy based on anatomic effects 

    • Individualize the use of dual inhibition therapy in patients with nAMD, DME, and RVO based on patient and disease characteristics, including response to previous therapy when applicable, using the best available evidence 

  • Accreditation and Credit Designation Statements

    Physician Accreditation Statement  
    Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physician Credit Designation Statement 

    Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    PA Continuing Education  

    PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Creditfrom organizations accredited by ACCME or a recognized state medical society. 

    Nurse Practitioner Continuing Education  

    The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines. 

  • Instructions for Participation

    To receive a certificate of participation, participants must: 

    • Follow instructions to register or log in with your professional information and complete the preassessment 

    • View the online activity in its entirety 

    • Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment 

     

    A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation. 
     
    For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com. 

     

    There are no fees for participating in this activity. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months. 

    All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

    The content of this activity was independentlyreviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated. 

    Arshad M. Khanani, MD, MA, FASRS 

    Consultant: 4D Molecular Therapeutics; AbbVie Inc; Adverum Biotechnologies, Inc; Alcon; Amgen Inc; Annexin Pharmaceuticals; Annexon, Inc; Apellis Pharmaceuticals, Inc; Aviceda Therapeutics; Beacon Therapeutics; Clearside BioMedical; Complement Therapeutics Ltd; Exegenesis Bio Co; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Frontera Therapeutics, Inc.; Genentech, Inc; Gyroscope Therapeutics Limited; i-Lumen Scientific; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiak Sciences Inc; Kriya Therapeutics; Nanoscope Therapeutics, Inc; Novartis AG; Ocular Therapeutix, Inc; Oculis; Ocuphire Pharma, Inc; OcuTerra Therapeutics; Olive BioPharma; Opthea; Oxular; Oxurion NV; Perfuse Therapeutics; Ray Therapeutics; RecensMedical Inc; Regeneron Pharmaceuticals Inc; REGENXBIO Inc; Revive Therapeutics; RevOpsis Therapeutics LLC; Sanofi; Stealth BioTherapeutics Inc; Thea Pharma Inc; UNITY Biotechnology; Vanotech; Vial 

    Speaker’s Bureau: IVERIC bio, Inc 

    Research Funding: 4D Molecular Therapeutics; Adverum Biotechnologies, Inc; Alexion Pharmaceuticals, Inc; Annexon, Inc; Apellis Pharmaceuticals, Inc; Aviceda Therapeutics; Exegenesis Bio Co; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Genentech, Inc; Gyroscope Therapeutics Limited; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiak Sciences Inc; Neurotech Pharmaceuticals, Inc; Ocular Therapeutix; Oculis; OcuTerra Therapeutics; Opthea; Oxular; Oxurion NV; REGENXBIO Inc; Vanotech; UNITY Biotechnology 

    Stocks: Aviceda Therapeutics; Oculis; Opthea; Perfuse Therapeutics; PolyPhotonix Medical Ltd; RecensMedical, Inc; RevOpsis Therapeutics; Vial 

     

    Karl Csaky, MD, PhD 

    Advisor: Adverum Biotechnologies, Inc 

    Consultant: AbbVie Inc.; Annexon, Inc; Cognition Therapeutics; EyeBio; Genentech, Inc; Heidelberg Engineering Inc; Johnson and Johnson Services, Inc; Merck & Co, Inc; NGM Biopharmaceuticals; Regeneron Pharmaceuticals Inc; Tenpoint Therapeutics  

    Speakers’ Bureau: Genentech, Inc 

    Research Funding: Annexon, Inc; Genentech, Inc; Johnson and Johnson Services, Inc; NGM Biopharmaceuticals; Regeneron Pharmaceuticals Inc 

    Stocks: Eye Bio 

     

    Christina Y. Weng, MD, MBA, FASRS  

    Consultant: AbbVie Inc.; Alcon; Alimera Sciences;Apellis Pharmaceuticals, Inc; DORC; EyePoint Pharmaceuticals, Inc; Genentech, Inc.; IVERIC bio, Inc; Novartis AG; Regeneron Pharmaceuticals Inc; REGENXBIO Inc. 

    Independent Contractor: agtc; Alimera Sciences 

     

    Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies todisclose. 

     

    Peer Reviewer 
    Stock: F. Hoffmann-La Roche Ltd (expired 3/24); Medtronic (expired 3/24); Pfizer Inc. (expired 3/24) 

    Disclosure of Unlabeled Use 

    This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. 

  • Disclaimer

    This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. 

    If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified. 

    As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.  

  • Terms of Use

    Disclaimer 

    The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of retinal vascular diseases. Dual inhibition therapy that acts on 2 pathways—VEGF-A and angiopoietin-2 (Ang-2)—is now available. Are 2 pathways better than 1? Find out in this engaging roundtable-style eye care forum, which will demonstrate direct comparisons of dual anti-Ang-2/VEGF-A therapy and anti-VEGF monotherapy, enhanced by real-life case studies and anecdotes from the expert faculty members’ own practices. 

  • Target Audience

    This activity has been designed to address the educational needs of retina specialists and comprehensive ophthalmologists. It may also benefit other clinicians involved in the care of patients with retinal vascular diseases.

  • Educational Provider

    This activity is provided by Paradigm Medical Communications, LLC.   

     

  • Commercial Support

    This activity is supported by an educational grant from Genentech, a member of the Roche Group.

  • Learning Objectives

    Upon completion of this activity, participants should be able to: 

    • Describe the significance of Ang-2 inhibition in combination with VEGF-A inhibition in the development and progression of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) 

    • Distinguish dual inhibition therapy from anti-VEGF therapy based on anatomic effects 

    • Individualize the use of dual inhibition therapy in patients with nAMD, DME, and RVO based on patient and disease characteristics, including response to previous therapy when applicable, using the best available evidence 

  • Accreditation and Credit Designation Statements

    Physician Accreditation Statement  
    Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physician Credit Designation Statement 

    Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    PA Continuing Education  

    PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Creditfrom organizations accredited by ACCME or a recognized state medical society. 

    Nurse Practitioner Continuing Education  

    The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines. 

  • Instructions for Participation

    To receive a certificate of participation, participants must: 

    • Follow instructions to register or log in with your professional information and complete the preassessment 

    • View the online activity in its entirety 

    • Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment 

     

    A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation. 
     
    For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com. 

     

    There are no fees for participating in this activity. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months. 

    All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

    The content of this activity was independentlyreviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated. 

    Arshad M. Khanani, MD, MA, FASRS 

    Consultant: 4D Molecular Therapeutics; AbbVie Inc; Adverum Biotechnologies, Inc; Alcon; Amgen Inc; Annexin Pharmaceuticals; Annexon, Inc; Apellis Pharmaceuticals, Inc; Aviceda Therapeutics; Beacon Therapeutics; Clearside BioMedical; Complement Therapeutics Ltd; Exegenesis Bio Co; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Frontera Therapeutics, Inc.; Genentech, Inc; Gyroscope Therapeutics Limited; i-Lumen Scientific; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiak Sciences Inc; Kriya Therapeutics; Nanoscope Therapeutics, Inc; Novartis AG; Ocular Therapeutix, Inc; Oculis; Ocuphire Pharma, Inc; OcuTerra Therapeutics; Olive BioPharma; Opthea; Oxular; Oxurion NV; Perfuse Therapeutics; Ray Therapeutics; RecensMedical Inc; Regeneron Pharmaceuticals Inc; REGENXBIO Inc; Revive Therapeutics; RevOpsis Therapeutics LLC; Sanofi; Stealth BioTherapeutics Inc; Thea Pharma Inc; UNITY Biotechnology; Vanotech; Vial 

    Speaker’s Bureau: IVERIC bio, Inc 

    Research Funding: 4D Molecular Therapeutics; Adverum Biotechnologies, Inc; Alexion Pharmaceuticals, Inc; Annexon, Inc; Apellis Pharmaceuticals, Inc; Aviceda Therapeutics; Exegenesis Bio Co; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Genentech, Inc; Gyroscope Therapeutics Limited; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiak Sciences Inc; Neurotech Pharmaceuticals, Inc; Ocular Therapeutix; Oculis; OcuTerra Therapeutics; Opthea; Oxular; Oxurion NV; REGENXBIO Inc; Vanotech; UNITY Biotechnology 

    Stocks: Aviceda Therapeutics; Oculis; Opthea; Perfuse Therapeutics; PolyPhotonix Medical Ltd; RecensMedical, Inc; RevOpsis Therapeutics; Vial 

     

    Karl Csaky, MD, PhD 

    Advisor: Adverum Biotechnologies, Inc 

    Consultant: AbbVie Inc.; Annexon, Inc; Cognition Therapeutics; EyeBio; Genentech, Inc; Heidelberg Engineering Inc; Johnson and Johnson Services, Inc; Merck & Co, Inc; NGM Biopharmaceuticals; Regeneron Pharmaceuticals Inc; Tenpoint Therapeutics  

    Speakers’ Bureau: Genentech, Inc 

    Research Funding: Annexon, Inc; Genentech, Inc; Johnson and Johnson Services, Inc; NGM Biopharmaceuticals; Regeneron Pharmaceuticals Inc 

    Stocks: Eye Bio 

     

    Christina Y. Weng, MD, MBA, FASRS  

    Consultant: AbbVie Inc.; Alcon; Alimera Sciences;Apellis Pharmaceuticals, Inc; DORC; EyePoint Pharmaceuticals, Inc; Genentech, Inc.; IVERIC bio, Inc; Novartis AG; Regeneron Pharmaceuticals Inc; REGENXBIO Inc. 

    Independent Contractor: agtc; Alimera Sciences 

     

    Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies todisclose. 

     

    Peer Reviewer 
    Stock: F. Hoffmann-La Roche Ltd (expired 3/24); Medtronic (expired 3/24); Pfizer Inc. (expired 3/24) 

    Disclosure of Unlabeled Use 

    This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. 

  • Disclaimer

    This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. 

    If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified. 

    As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.  

  • Terms of Use

    Disclaimer 

    The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule29 May 2024